Market Closed -
Nasdaq
16:00:00 2024-05-02 EDT
|
5-day change
|
1st Jan Change
|
36.3
USD
|
+0.17%
|
|
+8.85%
|
+42.58%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,748
|
3,259
|
1,369
|
1,413
|
2,227
|
-
|
-
|
Enterprise Value (EV)
1 |
2,453
|
2,819
|
809.9
|
976.4
|
1,711
|
1,764
|
1,679
|
P/E ratio
|
-19.7
x
|
-30.4
x
|
-8.7
x
|
-10.1
x
|
-12.3
x
|
-10.9
x
|
-10.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
80.7
x
|
44.7
x
|
29.2
x
|
18
x
|
41.8
x
|
29.9
x
|
31.3
x
|
EV / Revenue
|
72.1
x
|
38.7
x
|
17.3
x
|
12.4
x
|
32.1
x
|
23.7
x
|
23.6
x
|
EV / EBITDA
|
-55.1
x
|
-28.7
x
|
-5.12
x
|
-6.03
x
|
-8.56
x
|
-10.8
x
|
-10
x
|
EV / FCF
|
31
x
|
-21.6
x
|
-5.19
x
|
-7.11
x
|
-9.98
x
|
-9.91
x
|
-9.8
x
|
FCF Yield
|
3.22%
|
-4.63%
|
-19.3%
|
-14.1%
|
-10%
|
-10.1%
|
-10.2%
|
Price to Book
|
9.72
x
|
7.12
x
|
2.75
x
|
3.58
x
|
4.21
x
|
4.61
x
|
5.19
x
|
Nbr of stocks (in thousands)
|
44,326
|
51,332
|
54,865
|
55,487
|
61,358
|
-
|
-
|
Reference price
2 |
62.00
|
63.49
|
24.96
|
25.46
|
36.30
|
36.30
|
36.30
|
Announcement Date
|
21-03-11
|
22-02-24
|
23-02-23
|
24-02-22
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.934
|
34.03
|
72.83
|
46.83
|
78.59
|
53.25
|
74.46
|
71.11
|
EBITDA
1 |
-
|
-44.54
|
-98.13
|
-158.3
|
-162
|
-199.9
|
-164
|
-167.8
|
EBIT
1 |
-
|
-46.3
|
-100.5
|
-161.3
|
-165.5
|
-239.1
|
-253.5
|
-266.5
|
Operating Margin
|
-
|
-136.05%
|
-138.03%
|
-344.37%
|
-210.62%
|
-448.97%
|
-340.41%
|
-374.77%
|
Earnings before Tax (EBT)
1 |
-
|
-45.59
|
-100.2
|
-154.8
|
-147
|
-213.7
|
-260.8
|
-278.9
|
Net income
1 |
-
|
-54.64
|
-100.2
|
-154.8
|
-147
|
-208.7
|
-248.4
|
-262.8
|
Net margin
|
-
|
-160.55%
|
-137.6%
|
-330.6%
|
-186.99%
|
-391.93%
|
-333.63%
|
-369.53%
|
EPS
2 |
-
|
-3.150
|
-2.090
|
-2.870
|
-2.520
|
-2.958
|
-3.337
|
-3.570
|
Free Cash Flow
1 |
-
|
79.03
|
-130.5
|
-155.9
|
-137.3
|
-171.4
|
-178.1
|
-171.4
|
FCF margin
|
-
|
232.22%
|
-179.24%
|
-332.98%
|
-174.71%
|
-321.97%
|
-239.21%
|
-241.01%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-07-31
|
21-03-11
|
22-02-24
|
23-02-23
|
24-02-22
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
15.28
|
9.622
|
11.51
|
9.551
|
16.14
|
9.466
|
16.51
|
4.728
|
47.88
|
10.29
|
12.08
|
10.44
|
14.88
|
22.85
|
22.89
|
EBITDA
1 |
-33.3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-18.42
|
-51.44
|
-49.1
|
-64.64
|
-
|
-
|
-
|
EBIT
1 |
-33.99
|
-36.93
|
-40.81
|
-44.88
|
-38.63
|
-45.33
|
-43.38
|
-57.51
|
-19.31
|
-52.91
|
-55.56
|
-57.45
|
-60.74
|
-61.01
|
-63.9
|
Operating Margin
|
-222.55%
|
-383.84%
|
-354.44%
|
-469.92%
|
-239.36%
|
-478.83%
|
-262.72%
|
-1,216.35%
|
-40.33%
|
-514.3%
|
-459.9%
|
-550.11%
|
-408.14%
|
-267.06%
|
-279.19%
|
Earnings before Tax (EBT)
1 |
-33.9
|
-36.68
|
-40.26
|
-43
|
-34.86
|
-40.93
|
-38.8
|
-52.87
|
-14.37
|
-48.56
|
-51.69
|
-56.23
|
-52.4
|
-69.25
|
-73.25
|
Net income
1 |
-33.9
|
-36.68
|
-40.26
|
-43
|
-34.86
|
-40.93
|
-38.8
|
-52.87
|
-14.37
|
-48.56
|
-51.25
|
-52.33
|
-55.01
|
-69.25
|
-73.25
|
Net margin
|
-221.93%
|
-381.25%
|
-349.64%
|
-450.24%
|
-216.03%
|
-432.37%
|
-234.96%
|
-1,118.17%
|
-30.01%
|
-472.02%
|
-424.15%
|
-501.05%
|
-369.64%
|
-303.12%
|
-320.05%
|
EPS
2 |
-0.6700
|
-0.7100
|
-0.7800
|
-0.7900
|
-0.5900
|
-0.7000
|
-0.6700
|
-0.9000
|
-0.2500
|
-0.6900
|
-0.6750
|
-0.7400
|
-0.8200
|
-0.6440
|
-0.7063
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-02-24
|
22-05-03
|
22-08-09
|
22-11-03
|
23-02-23
|
23-05-04
|
23-08-03
|
23-11-02
|
24-02-22
|
24-05-02
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
295
|
440
|
559
|
436
|
516
|
463
|
549
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
79
|
-131
|
-156
|
-137
|
-171
|
-178
|
-171
|
ROE (net income / shareholders' equity)
|
-
|
-52.2%
|
-27%
|
-32.6%
|
-33.2%
|
-34.6%
|
-36.6%
|
-56.7%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-18.3%
|
-25.6%
|
-24.9%
|
-33.5%
|
-31.2%
|
-40.2%
|
Assets
1 |
-
|
-
|
546.5
|
604.5
|
589.4
|
623
|
796.3
|
653.7
|
Book Value Per Share
2 |
-
|
6.380
|
8.920
|
9.090
|
7.110
|
8.610
|
7.870
|
7.000
|
Cash Flow per Share
2 |
-
|
5.080
|
-2.690
|
-2.840
|
-1.760
|
1.050
|
-3.650
|
-2.320
|
Capex
1 |
-
|
9.1
|
1.6
|
2.84
|
34.5
|
7.28
|
7.39
|
6.93
|
Capex / Sales
|
-
|
26.73%
|
2.19%
|
6.06%
|
43.87%
|
13.68%
|
9.92%
|
9.75%
|
Announcement Date
|
20-07-31
|
21-03-11
|
22-02-24
|
23-02-23
|
24-02-22
|
-
|
-
|
-
|
Last Close Price
36.3
USD Average target price
51
USD Spread / Average Target +40.50% Consensus |
1st Jan change
|
Capi.
|
---|
| +42.58% | 2.23B | | +26.28% | 48.09B | | -3.99% | 40.43B | | +45.32% | 40.62B | | -6.20% | 28.36B | | +6.36% | 24.89B | | -21.47% | 19.01B | | +27.58% | 12.09B | | -2.75% | 11.8B | | -2.02% | 11.88B |
Other Biotechnology & Medical Research
|